Federal Circuit says Pfizer arthritis drug was double patented

24-06-2015

Federal Circuit says Pfizer arthritis drug was double patented

pio3 / Shutterstock.com

The US Court of Appeals for the Federal Circuit has affirmed a lower court ruling which said that a reissue patent covering Pfizer’s arthritis drug Celebrex (celecoxib) was invalid for obviousness-type double patenting.


obviousness-type double patenting, US Court of Appeals for the Federal Circuit, Pfizer, Celebrex

LSIPR